TRV
56
-2
NKE
33
2
LOW
58
2
FDX
54
14
STX
52
-4
MMM
42
5
MS
80
-3
CNP
50
-2
DRI
56
2
TEL
74
3
NWSA
71
-2
OXY
55
6
STZ
58
3
BA
45
-3
HUM
48
2
FRT
48
2
LB
63
-4
CSX
68
3
VNO
60
8
SLG
62
-4
TRV
56
-2
NKE
33
2
LOW
58
2
FDX
54
14
STX
52
-4
MMM
42
5
MS
80
-3
CNP
50
-2
DRI
56
2
TEL
74
3
NWSA
71
-2
OXY
55
6
STZ
58
3
BA
45
-3
HUM
48
2
FRT
48
2
LB
63
-4
CSX
68
3
VNO
60
8
SLG
62
-4
Financhill
Back

Fulcrum Therapeutics 10K Form

Sell
47

FULC
Fulcrum Therapeutics

Last Price:
3.32
Seasonality Move:
67.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive FULC News And Ratings

See the #1 stock for the next 7 days that we like better than FULC

FULC Financial Statistics

Sales & Book Value

Annual Sales: $2.81M
Cash Flow: $58.9M
Price / Cash Flow: 0
Annual Sales: $4.40
Price / Book: 0.83

Profitability

EPS (TTM): -0.35000
Net Income (TTM): $-20.23M
Gross Margin: --
Return on Equity: -8.07%
Return on Assets: -7.42%

Fulcrum Therapeutics Earnings Forecast

Key Fulcrum Therapeutics Financial Ratios

  • The Research & Development expenses have been 2,559.75% of Revenue.
  • The Net Earning history of FULC is -3,470.05% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 4 years.

Fulcrum Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: FULC
CUSIP: 359616
Website: fulcrumtx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 22.07
Quick Ratio: 21.84

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FULC Technical Analysis vs Fundamental Analysis

Sell
47
Fulcrum Therapeutics (FULC) is a Sell

Is Fulcrum Therapeutics a Buy or a Sell?